Skip to main content
. 2022 Jun 13;12(1):61–72. doi: 10.1002/cam4.4937

FIGURE 3.

FIGURE 3

(A) Overall survival and (B) time to progression in patients in the LIDA and LEN groups. Dotted lines represent the 95% confidence interval. Abbreviations: CI, confident interval; LIDA group, patients treated with lenvatinib plus idarubicin‐loaded drug‐eluting beads transarterial chemoembolization; LEN group, patients treated with lenvatinib alone.